Watson Biosimilar Tie Up With Itero Plays Into Women's Health Expertise
This article was originally published in The Pink Sheet Daily
Watson licenses rights to a recombinant follicle stimulating hormone in preclinical development that would reference Merck-Serono's infertility drug Gonal-f.
You may also be interested in...
Fertility Market Poised For Growth Spurt After Fallow Decade
Late-stage pipeline is dominated by follicle stimulating hormones, split between “biobetters” and biosimilars. Next-generation oxytocin antagonists are leading candidates for the next novel entities in infertility.
Are Potential Biosimilar Sponsors Still Hesitant About The Pathway Despite Expected Growth?
IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.
Two Deals Bolster Watson's Position In Branded Women's Health Products
Branded drugs may earn only a fraction of Watson's generics, but firm sees overlapping opportunity in urology and women's health care.